Shitij Kapur

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/3463824/publications.pdf

Version: 2024-02-01

311	39,401	2322	2953
papers	citations	98 h-index	189 g-index

319	319	319	28131
all docs	docs citations	times ranked	citing authors

#	Article	IF	Citations
1	Psychosis as a State of Aberrant Salience: A Framework Linking Biology, Phenomenology, and Pharmacology in Schizophrenia. American Journal of Psychiatry, 2003, 160, 13-23.	7.2	2,311
2	The Dopamine Hypothesis of Schizophrenia: Version III--The Final Common Pathway. Schizophrenia Bulletin, 2009, 35, 549-562.	4.3	2,149
3	Schizophrenia. Lancet, The, 2009, 374, 635-645.	13.7	1,820
4	Grand challenges in global mental health. Nature, 2011, 475, 27-30.	27.8	1,654
5	Does Fast Dissociation From the Dopamine D₂Receptor Explain the Action of Atypical Antipsychotics?: A New Hypothesis. American Journal of Psychiatry, 2001, 158, 360-369.	7.2	1,131
6	Relationship Between Dopamine D2 Occupancy, Clinical Response, and Side Effects: A Double-Blind PET Study of First-Episode Schizophrenia. American Journal of Psychiatry, 2000, 157, 514-520.	7.2	982
7	Why has it taken so long for biological psychiatry to develop clinical tests and what to do about it?. Molecular Psychiatry, 2012, 17, 1174-1179.	7.9	883
8	The Nature of Dopamine Dysfunction in Schizophrenia and What This Means for Treatment. Archives of General Psychiatry, 2012, 69, 776-86.	12.3	769
9	Age-Related Differences in Neural Activity during Memory Encoding and Retrieval: A Positron Emission Tomography Study. Journal of Neuroscience, 1997, 17, 391-400.	3.6	692
10	Opposite Effects of Î”-9-Tetrahydrocannabinol and Cannabidiol on Human Brain Function and Psychopathology. Neuropsychopharmacology, 2010, 35, 764-774.	5.4	595
11	CNVs conferring risk of autism or schizophrenia affect cognition in controls. Nature, 2014, 505, 361-366.	27.8	588
12	Half a century of antipsychotics and still a central role for dopamine D2 receptors. Progress in Neuro-Psychopharmacology and Biological Psychiatry, 2003, 27, 1081-1090.	4.8	520
13	From dopamine to salience to psychosisâ€”linking biology, pharmacology and phenomenology of psychosis. Schizophrenia Research, 2005, 79, 59-68.	2.0	433
14	Antipsychotic Dosing in Preclinical Models Is Often Unrepresentative of the Clinical Condition: A Suggested Solution Based on in Vivo Occupancy. Journal of Pharmacology and Experimental Therapeutics, 2003, 305, 625-631.	2.5	431
15	NMDA receptor antagonists ketamine and PCP have direct effects on the dopamine D2 and serotonin 5-HT2 receptorsâ€”implications for models of schizophrenia. Molecular Psychiatry, 2002, 7, 837-844.	7.9	416
16	Direct Activation of the Ventral Striatum in Anticipation of Aversive Stimuli. Neuron, 2003, 40, 1251-1257.	8.1	405
17	Delayed-Onset Hypothesis of Antipsychotic Action. Archives of General Psychiatry, 2003, 60, 1228.	12.3	398
18	Cannabidiol inhibits THC-elicited paranoid symptoms and hippocampal-dependent memory impairment. Journal of Psychopharmacology, 2013, 27, 19-27.	4.0	373

#	Article	IF	Citations
19	5-HT₂and D₂Receptor Occupancy of Olanzapine in Schizophrenia: A PET Investigation. American Journal of Psychiatry, 1998, 155, 921-928.	7.2	359
20	Dopamine D2 receptors and their role in atypical antipsychotic action: still necessary and may even be sufficient. Biological Psychiatry, 2001, 50, 873-883.	1.3	339
21	Role of the dopaminergic system in depression. Biological Psychiatry, 1992, 32, 1-17.	1.3	318
22	Negative symptoms have greater impact on functioning than positive symptoms in schizophrenia: Analysis of CATIE data. Schizophrenia Research, 2012, 137, 147-150.	2.0	305
23	Functional role of the prefrontal cortex in retrieval of memories: a PET study. NeuroReport, 1995, 6, 1880-1884.	1.2	303
24	Neuroanatomical Correlates of Human Reasoning. Journal of Cognitive Neuroscience, 1998, 10, 293-302.	2.3	294
25	Atypical Antipsychotics: New Directions and New Challenges in the Treatment of Schizophrenia. Annual Review of Medicine, 2001, 52, 503-517.	12.2	293
26	Dopamine Synthesis Capacity in Patients With Treatment-Resistant Schizophrenia. American Journal of Psychiatry, 2012, 169, 1203-1210.	7.2	291
27	The seats of reason? An imaging study of deductive and inductive reasoning. NeuroReport, 1997, 8, 1305-1310.	1.2	281
28	Adherence to treatment guidelines in clinical practice: study of antipsychotic treatment prior to clozapine initiation. British Journal of Psychiatry, 2012, 201, 481-485.	2.8	280
29	Antipsychotic Treatment Resistance in Schizophrenia Associated with Elevated Glutamate Levels but Normal Dopamine Function. Biological Psychiatry, 2014, 75, e11-e13.	1.3	280
30	The acute effects of synthetic intravenous Î”9-tetrahydrocannabinol on psychosis, mood and cognitive functioning. Psychological Medicine, 2009, 39, 1607.	4.5	259
31	Evidence for Impaired Cortical Inhibition in Schizophrenia Using Transcranial Magnetic Stimulation. Archives of General Psychiatry, 2002, 59, 347.	12.3	256
32	Increased dopamine D 2 receptor binding after long-term treatment with antipsychotics in humans: a clinical PET study. Psychopharmacology, 2000, 152, 174-180.	3.1	249
33	Schizophrenia: More dopamine, more D₂receptors. Proceedings of the National Academy of Sciences of the United States of America, 2000, 97, 7673-7675.	7.1	241
34	â€œBreakthroughâ€•Dopamine Supersensitivity during Ongoing Antipsychotic Treatment Leads to Treatment Failure over Time. Journal of Neuroscience, 2007, 27, 2979-2986.	3.6	235
35	Differential Effects of Aripiprazole on D₂, 5-HT₂, and 5-HT_{1A}Receptor Occupancy in Patients With Schizophrenia: A Triple Tracer PET Study. American Journal of Psychiatry, 2007, 164, 1411-1417.	7.2	235
36	The role of the left prefrontal cortex in verbal processing. NeuroReport, 1994, 5, 2193-2196.	1.2	223

#	Article	IF	Citations
37	The Effect of Paroxetine on 5-HT_{2A}Receptors in Depression: An [¹⁸F]Setoperone PET Imaging Study. American Journal of Psychiatry, 2001, 158, 78-85.	7.2	222
38	Radiosynthesis and Evaluation of [11C]-(+)-4-Propyl-3,4,4a,5,6,10b-hexahydro-2H-naphtho[1,2-b][1,4]oxazin-9-ol as a Potential Radiotracer for in Vivo Imaging of the Dopamine D2 High-Affinity State with Positron Emission Tomography. Journal of Medicinal Chemistry, 2005, 48, 4153-4160.	6.4	218
39	Functional Neuroanatomy of Recall and Recognition: A PET Study of Episodic Memory. Journal of Cognitive Neuroscience, 1997, 9, 254-265.	2.3	214
40	Dopamine D2 Receptor Occupancy Is a Common Mechanism Underlying Animal Models of Antipsychotics and Their Clinical Effects. Neuropsychopharmacology, 2001, 25, 633-641.	5.4	214
41	Mechanisms Underlying Psychosis and Antipsychotic Treatment Response in Schizophrenia: Insights from PET and SPECT Imaging. Current Pharmaceutical Design, 2009, 15, 2550-2559.	1.9	213
42	The Effects of Divided Attention on Encoding- and Retrieval-Related Brain Activity: A PET Study of Younger and Older Adults. Journal of Cognitive Neuroscience, 2000, 12, 775-792.	2.3	208
43	The D2 dopamine receptor occupancy of risperidone and its relationship to extrapyramidal symptoms: A pet study. Life Sciences, 1995, 57, PL103-PL107.	4.3	204
44	Elevation of Prolactin Levels by Atypical Antipsychotics. American Journal of Psychiatry, 2002, 159, 133-135.	7.2	199
45	Alterations of the Brain Reward System in Antipsychotic NaÃ¯ve Schizophrenia Patients. Biological Psychiatry, 2012, 71, 898-905.	1.3	197
46	The Formation of Abnormal Associations in Schizophrenia: Neural and Behavioral Evidence. Neuropsychopharmacology, 2008, 33, 473-479.	5.4	195
47	Dissociation between In Vivo Occupancy and Functional Antagonism of Dopamine D2 Receptors: Comparing Aripiprazole to Other Antipsychotics in Animal Models. Neuropsychopharmacology, 2006, 31, 1854-1863.	5.4	194
48	Evidence for Onset of Antipsychotic Effects Within the First 24 Hours of Treatment. American Journal of Psychiatry, 2005, 162, 939-946.	7.2	193
49	A PET Study of Dopamine D2and Serotonin 5-HT2Receptor Occupancy in Patients With Schizophrenia Treated With Therapeutic Doses of Ziprasidone. American Journal of Psychiatry, 2004, 161, 818-825.	7.2	188
50	Dopamine Specifically Inhibits Forebrain Neural Stem Cell Proliferation, Suggesting a Novel Effect of Antipsychotic Drugs. Journal of Neuroscience, 2005, 25, 5815-5823.	3.6	188
51	The amphetamine-induced sensitized state as a model of schizophrenia. Progress in Neuro-Psychopharmacology and Biological Psychiatry, 2007, 31, 1556-1571.	4.8	186
52	An Algorithm-Based Approach to First-Episode Schizophrenia. Journal of Clinical Psychiatry, 2011, 72, 1439-1444.	2.2	186
53	Specific and Generalized Neuropsychological Deficits: A Comparison of Patients With Various First-Episode Psychosis Presentations. American Journal of Psychiatry, 2010, 167, 78-85.	7.2	175
54	Dopaminergic Function in Cannabis Users and Its Relationship to Cannabis-Induced Psychotic Symptoms. Biological Psychiatry, 2014, 75, 470-478.	1.3	170

#	Article	IF	Citations
55	Effect of Chronic Antipsychotic Treatment on Brain Structure: A Serial Magnetic Resonance Imaging Study with Ex Vivo and Postmortem Confirmation. Biological Psychiatry, 2011, 69, 936-944.	1.3	166
56	A neurobiological hypothesis for the classification of schizophrenia: type a (hyperdopaminergic) and type B (normodopaminergic). British Journal of Psychiatry, 2014, 205, 1-3.	2.8	166
57	Early Response to Antipsychotic Drug Therapy as a Clinical Marker of Subsequent Response in the Treatment of Schizophrenia. Neuropsychopharmacology, 2010, 35, 581-590.	5.4	165
58	Separate brain regions code for salience vs. valence during reward prediction in humans. Human Brain Mapping, 2007, 28, 294-302.	3.6	163
59	The feasibility and validity of ambulatory self-report of psychotic symptoms using a smartphone software application. BMC Psychiatry, 2012, 12, 172.	2.6	161
60	The neural correlates of intentional learning of verbal materials: A PET study in humans. Cognitive Brain Research, 1996, 4, 243-249.	3.0	156
61	Dissociation of pathways for object and spatial vision: a PET study in humans. NeuroReport, 1995, 6, 1865-1868.	1.2	154
62	Dopamine D 2 receptor occupancy predicts catalepsy and the suppression of conditioned avoidance response behavior in rats. Psychopharmacology, 2000, 150, 422-429.	3.1	153
63	The Differential Effects of Atypical Antipsychotics on Prolactin Elevation Are Explained by Their Differential Blood-Brain Disposition: A Pharmacological Analysis in Rats. Journal of Pharmacology and Experimental Therapeutics, 2002, 302, 1129-1134.	2.5	148
64	An automated method for the extraction of regional data from PET images. Psychiatry Research - Neuroimaging, 2006, 147, 79-89.	1.8	148
65	Equivalent Occupancy of Dopamine D₁and D₂Receptors With Clozapine: Differentiation From Other Atypical Antipsychotics. American Journal of Psychiatry, 2004, 161, 1620-1625.	7.2	146
66	Binding characteristics and sensitivity to endogenous dopamine of [11C]-(+)-PHNO, a new agonist radiotracer for imaging the high-affinity state of D2 receptors in vivo using positron emission tomography. Journal of Neurochemistry, 2006, 97, 1089-1103.	3.9	145
67	A Positron Emission Tomography Study of Silent and Oral Single Word Reading in Stuttering and Nonstuttering Adults. Journal of Speech, Language, and Hearing Research, 2000, 43, 1038-1053.	1.6	141
68	Adverse Subjective Experience With Antipsychotics and Its Relationship to Striatal and Extrastriatal D₂Receptors: a PET Study in Schizophrenia. American Journal of Psychiatry, 2007, 164, 630-637.	7.2	141
69	Amisulpride and olanzapine followed by open-label treatment with clozapine in first-episode schizophrenia and schizophreniform disorder (OPTiMiSE): a three-phase switching study. Lancet Psychiatry,the, 2018, 5, 797-807.	7.4	141
70	Temporal Difference Modeling of the Blood-Oxygen Level Dependent Response During Aversive Conditioning in Humans: Effects of Dopaminergic Modulation. Biological Psychiatry, 2007, 62, 765-772.	1.3	138
71	Improvement of Brain Reward Abnormalities by Antipsychotic Monotherapy in Schizophrenia. Archives of General Psychiatry, 2012, 69, 1195.	12.3	137
72	Inverse Relationship Between Serotonin 5-HT1AReceptor Binding and Anxiety: A [11C]WAY-100635 PET Investigation in Healthy Volunteers. American Journal of Psychiatry, 2001, 158, 1326-1328.	7.2	134

#	Article	IF	Citations
73	Cerebral Gray Matter Volume Deficits in First Episode Psychosis. Archives of General Psychiatry, 1998, 55, 540.	12.3	133
74	A PET Study Evaluating Dopamine D2Receptor Occupancy for Long-Acting Injectable Risperidone. American Journal of Psychiatry, 2006, 163, 396-401.	7.2	132
75	Integrating mobile-phone based assessment for psychosis into peopleâ€™s everyday lives and clinical care: a qualitative study. BMC Psychiatry, 2013, 13, 34.	2.6	130
76	White matter integrity as a predictor of response to treatment in first episode psychosis. Brain, 2014, 137, 172-182.	7.6	130
77	Brain Serotonin 5-HT1A Receptor Binding in Schizophrenia Measured by Positron Emission Tomography and [11C]WAY-100635. Archives of General Psychiatry, 2002, 59, 514.	12.3	130
78	High-Affinity States of Human Brain Dopamine D2/3 Receptors Imaged by the Agonist [11C]-(+)-PHNO. Biological Psychiatry, 2006, 59, 389-394.	1.3	129
79	A Comparison of Two Delivery Modalities of a Mobile Phone-Based Assessment for Serious Mental Illness: Native Smartphone Application vs Text-Messaging Only Implementations. Journal of Medical Internet Research, 2013, 15, e60.	4.3	128
80	Advantages and disadvantages of combination treatment with antipsychotics. European Neuropsychopharmacology, 2009, 19, 520-532.	0.7	125
81	Jumping to conclusions, a lack of belief flexibility and delusional conviction in psychosis: A longitudinal investigation of the structure, frequency, and relatedness of reasoning biases.. Journal of Abnormal Psychology, 2012, 121, 129-139.	1.9	123
82	A model of anticholinergic activity of atypical antipsychotic medications. Schizophrenia Research, 2006, 88, 63-72.	2.0	121
83	Determinants of treatment response in first-episode psychosis: an 18F-DOPA PET study. Molecular Psychiatry, 2019, 24, 1502-1512.	7.9	120
84	The Effect of Divided Attention on Encoding and Retrieval in Episodic Memory Revealed by Positron Emission Tomography. Journal of Cognitive Neuroscience, 2000, 12, 267-280.	2.3	119
85	The relationship between D 2 receptor occupancy and plasma levels on low dose oral haloperidol: a PET study. Psychopharmacology, 1997, 131, 148-152.	3.1	118
86	Striatal Vs Extrastriatal Dopamine D2 Receptors in Antipsychotic Responseâ€”A Double-Blind PET Study in Schizophrenia. Neuropsychopharmacology, 2007, 32, 1209-1215.	5.4	118
87	Translating genome-wide association findings into new therapeutics for psychiatry. Nature Neuroscience, 2016, 19, 1392-1396.	14.8	115
88	Sensitization to amphetamine, but not PCP, impairs attentional set shifting: reversal by a D1 receptor agonist injected into the medial prefrontal cortex. Psychopharmacology, 2005, 183, 190-200.	3.1	113
89	Contrasting Effects of Haloperidol and Lithium on Rodent Brain Structure: A Magnetic Resonance Imaging Study with Postmortem Confirmation. Biological Psychiatry, 2012, 71, 855-863.	1.3	113
90	Meta-Regression Analysis of Placebo Response in Antipsychotic Trials, 1970â€“2010. American Journal of Psychiatry, 2013, 170, 1335-1344.	7.2	112

#	Article	IF	Citations
91	Genetic Predictors of Response to Serotonergic and Noradrenergic Antidepressants in Major Depressive Disorder: A Genome-Wide Analysis of Individual-Level Data and a Meta-Analysis. PLoS Medicine, 2012, 9, e1001326.	8.4	110
92	First Human Evidence of d-Amphetamine Induced Displacement of a D2/3 Agonist Radioligand: A [11C]-(+)-PHNO Positron Emission Tomography Study. Neuropsychopharmacology, 2008, 33, 279-289.	5.4	109
93	The Dopamine D2 Receptors in High-Affinity State and D3 Receptors in Schizophrenia: A Clinical [11C]-(+)-PHNO PET Study. Neuropsychopharmacology, 2009, 34, 1078-1086.	5.4	109
94	Serotonin 5-HT₂Receptors in Schizophrenia: A PET Study Using [¹⁸F]Setoperone in Neuroleptic-Naive Patients and Normal Subjects. American Journal of Psychiatry, 1999, 156, 72-78.	7.2	108
95	How antipsychotics become anti-â€˜psychoticâ€™ â€“ from dopamine to salience to psychosis. Trends in Pharmacological Sciences, 2004, 25, 402-406.	8.7	108
96	Apathy in schizophrenia: clinical correlates and association with functional outcome. Schizophrenia Research, 2003, 63, 79-88.	2.0	106
97	Role of Dopamine D2 Receptors for Antipsychotic Activity. Handbook of Experimental Pharmacology, 2012, , 27-52.	1.8	106
98	Gestational Methylazoxymethanol Acetate Treatment Impairs Select Cognitive Functions: Parallels to Schizophrenia. Neuropsychopharmacology, 2007, 32, 483-492.	5.4	104
99	Less Is More: Antipsychotic Drug Effects Are Greater with Transient Rather Than Continuous Delivery. Biological Psychiatry, 2008, 64, 145-152.	1.3	104
100	Increased Antipsychotic Sensitivity in Elderly Patients. Journal of Clinical Psychiatry, 2009, 70, 397-405.	2.2	104
101	Loss of phosphodiesterase 10A expression is associated with progression and severity in Parkinsonâ€™s disease. Brain, 2015, 138, 3003-3015.	7.6	100
102	Increased Dopamine D₂Receptor Occupancy and Elevated Prolactin Level Associated With Addition of Haloperidol to Clozapine. American Journal of Psychiatry, 2001, 158, 311-314.	7.2	99
103	Alterations in cortical and extrastriatal subcortical dopamine function in schizophrenia: systematic review and meta-analysis of imaging studies. British Journal of Psychiatry, 2014, 204, 420-429.	2.8	98
104	â€˜Jumping to conclusionsâ€™ and delusions in psychosis: Relationship and response to treatment. Schizophrenia Research, 2008, 98, 225-231.	2.0	97
105	The Effect of Antipsychotics on the High-Affinity State of D2 and D3 Receptors. Archives of General Psychiatry, 2009, 66, 606.	12.3	97
106	Acute effects of singleâ€dose aripiprazole and haloperidol on resting cerebral blood flow (rCBF) in the human brain. Human Brain Mapping, 2013, 34, 272-282.	3.6	97
107	Brain region binding of the D2/3 agonist [11C]-(+)-PHNO and the D2/3 antagonist [11C]raclopride in healthy humans. Human Brain Mapping, 2008, 29, 400-410.	3.6	95
108	Microvascular Abnormality in Schizophrenia as Shown by Retinal Imaging. American Journal of Psychiatry, 2013, 170, 1451-1459.	7.2	95

#	Article	IF	Citations
109	Decreased binding of the D3 dopamine receptor-preferring ligand [11C]-(+)-PHNO in drug-naive Parkinson's disease. Brain, 2009, 132, 1366-1375.	7.6	93
110	The Promise of Biological Markers for Treatment Response in First-Episode Psychosis: A Systematic Review. Schizophrenia Bulletin, 2015, 41, 559-573.	4.3	93
111	A Systematic Review of Aripiprazoleâ€"Dose, Plasma Concentration, Receptor Occupancy, and Response. Journal of Clinical Psychiatry, 2010, 71, 1447-1456.	2.2	93
112	PET Evidence That Loxapine Is an Equipotent Blocker of 5-HT₂and D₂Receptors: Implications for the Therapeutics of Schizophrenia. American Journal of Psychiatry, 1997, 154, 1525-1529.	7.2	92
113	Altered PDE10A expression detectable early before symptomatic onset in Huntingtonâ€™s disease. Brain, 2015, 138, 3016-3029.	7.6	90
114	Cognitive Subtractions May Not Add Up: The Interaction between Semantic Processing and Response Mode. NeuroImage, 1997, 5, 229-239.	4.2	89
115	Positron Emission Tomography Quantification of [11C]-(+)-PHNO Binding in the Human Brain. Journal of Cerebral Blood Flow and Metabolism, 2007, 27, 857-871.	4.3	88
116	Pharmacogenetics in Psychiatry: Are We Ready for Widespread Clinical Use?. Schizophrenia Bulletin, 2008, 34, 1130-1144.	4.3	88
117	Clinically meaningful biomarkers for psychosis: A systematic and quantitative review. Neuroscience and Biobehavioral Reviews, 2014, 45, 134-141.	6.1	87
118	Amphetamine-sensitized animals show a sensorimotor gating and neurochemical abnormality similar to that of schizophrenia. Schizophrenia Research, 2003, 64, 103-114.	2.0	86
119	The link between dopamine function and apathy in cannabis users: an [18F]-DOPA PET imaging study. Psychopharmacology, 2014, 231, 2251-2259.	3.1	86
120	Reduced Cortical Volume and Elevated Astrocyte Density in Rats Chronically Treated With Antipsychotic Drugsâ€"Linking Magnetic Resonance Imaging Findings to Cellular Pathology. Biological Psychiatry, 2014, 75, 982-990.	1.3	85
121	Does intravenous Î”9-tetrahydrocannabinol increase dopamine release? A SPET study. Journal of Psychopharmacology, 2011, 25, 1462-1468.	4.0	84
122	Biomarkers for Psychiatry: The Journey from Fantasy to Fact, a Report of the 2013 CINP Think Tank: Figure 1.. International Journal of Neuropsychopharmacology, 2015, 18, pyv042.	2.1	84
123	The "delayed onset" of antipsychotic action--an idea whose time has come and gone. Journal of Psychiatry and Neuroscience, 2006, 31, 93-100.	2.4	84
124	Early Use of Clozapine for Poorly Responding First-Episode Psychosis. Journal of Clinical Psychopharmacology, 2007, 27, 369-373.	1.4	82
125	Schizophrenia, amphetamine-induced sensitized state and acute amphetamine exposure all show a common alteration: increased dopamine D2 receptor dimerization. Molecular Brain, 2010, 3, 25.	2.6	79
126	D2-Receptor Upregulation is Dependent upon Temporal Course of D2-Occupancy: A Longitudinal [11C]-Raclopride PET Study in Cats. Neuropsychopharmacology, 2009, 34, 662-671.	5.4	78

#	Article	IF	Citations
127	Effects of antipsychotics on D3 receptors: A clinical PET study in first episode antipsychotic naive patients with schizophrenia using [11C]-(+)-PHNO. Schizophrenia Research, 2011, 131, 63-68.	2.0	78
128	How antipsychotics workâ€"From receptors to reality. NeuroRx, 2006, 3, 10-21.	6.0	77
129	Microglial activation in the rat brain following chronic antipsychotic treatment at clinically relevant doses. European Neuropsychopharmacology, 2015, 25, 2098-2107.	0.7	77
130	Effects of catecholamine depletion on D2 receptor binding, mood, and attentiveness in humans: a replication study. Pharmacology Biochemistry and Behavior, 2003, 74, 425-432.	2.9	76
131	The Dopamine Stabilizers (S)-(-)-(3-Methanesulfonyl-phenyl)-1-propyl-piperidine [(-)-OSU6162] and 4-(3-Methanesulfonylphenyl)-1-propyl-piperidine (ACR16) Show High in Vivo D2 Receptor Occupancy, Antipsychotic-Like Efficacy, and Low Potential for Motor Side Effects in the Rat. Journal of Pharmacology and Experimental Therapeutics, 2006, 318, 810-818.	2.5	75
132	Choosing the Right Dose of Antipsychotics in Schizophrenia. CNS Drugs, 2001, 15, 671-678.	5.9	74
133	Sensitization to amphetamine, but not phencyclidine, disrupts prepulse inhibition and latent inhibition. Psychopharmacology, 2005, 180, 366-376.	3.1	74
134	Disruption of Frontal Theta Coherence by Î"9-Tetrahydrocannabinol is Associated with Positive Psychotic Symptoms. Neuropsychopharmacology, 2011, 36, 827-836.	5.4	74
135	Amphetamine-sensitized animals show a marked increase in dopamine D2 high receptors occupied by endogenous dopamine, even in the absence of acute challenges. Synapse, 2002, 46, 235-239.	1.2	73
136	Pharmacogenetics of antidepressant response: A polygenic approach. Progress in Neuro-Psychopharmacology and Biological Psychiatry, 2017, 75, 128-134.	4.8	71
137	Is amoxapine an atypical antipsychotic? positron-emission tomography investigation of its dopamine2 and serotonin2 occupancy. Biological Psychiatry, 1999, 45, 1217-1220.	1.3	70
138	Are Animal Studies of Antipsychotics Appropriately Dosed?: Lessons from the Bedside to the Bench. Canadian Journal of Psychiatry, 2000, 45, 241-246.	1.9	70
139	Anesthetics inhibit high-affinity states of dopamine D2 and other G-linked receptors. Synapse, 2003, 50, 35-40.	1.2	69
140	A Sensitizing Regimen of Amphetamine Impairs Visual Attention in the 5-Choice Serial Reaction Time Test: Reversal by a D1 Receptor Agonist Injected into the Medial Prefrontal Cortex. Neuropsychopharmacology, 2007, 32, 1122-1132.	5.4	69
141	Pharmacotherapy of first-episode schizophrenia. British Journal of Psychiatry, 1998, 172, 66-70.	2.8	68
142	Time Course of the Antipsychotic Effect and the Underlying Behavioral Mechanisms. Neuropsychopharmacology, 2007, 32, 263-272.	5.4	65
143	D2 Receptor Occupancy of Olanzapine Pamoate Depot Using Positron Emission Tomography: An Open-label Study in Patients with Schizophrenia. Neuropsychopharmacology, 2008, 33, 298-304.	5.4	65
144	Dopamine D2 and D3 receptors in human putamen, caudate nucleus, and globus pallidus. Synapse, 2006, 60, 205-211.	1.2	64

#	Article	IF	Citations
145	The effect of antipsychotic treatment on Theory of Mind. Psychological Medicine, 2007, 37, 595.	4.5	64
146	Amisulpride the â€˜atypicalâ€™ atypical antipsychotic â€” Comparison to haloperidol, risperidone and clozapine. Schizophrenia Research, 2008, 105, 224-235.	2.0	64
147	A putative animal model of the â€œprodromalâ€•state of schizophrenia. Biological Psychiatry, 2005, 57, 586-593.	1.3	63
148	Blockade of [11C](+)-PHNO binding in human subjects by the dopamine D3 receptor antagonist ABT-925. International Journal of Neuropsychopharmacology, 2010, 13, 273.	2.1	63
149	Dopamine, prediction error and associative learning: A model-based account. Network: Computation in Neural Systems, 2006, 17, 61-84.	3.6	62
150	Antipsychotic Dosing: How Much but also How Often?. Schizophrenia Bulletin, 2010, 36, 900-903.	4.3	60
151	Negative symptoms in schizophrenia â€“ the remarkable impact of inclusion definitions in clinical trials and their consequences. Schizophrenia Research, 2013, 150, 334-338.	2.0	59
152	Efficacy and safety of adjunctive bitopertin versus placebo in patients with suboptimally controlled symptoms of schizophrenia treated with antipsychotics: results from three phase 3, randomised, double-blind, parallel-group, placebo-controlled, multicentre studies in the SearchLyte clinical trial programme. Lancet Psychiatry,the, 2016, 3, 1115-1128.	7.4	59
153	Effects of self-generated sad mood on regional cerebral activity: A PET study in normal subjects. Depression, 1996, 4, 81-88.	0.6	58
154	The relationship between dopamine D2 receptor occupancy and the vacuous chewing movement syndrome in rats. Psychopharmacology, 2003, 165, 166-171.	3.1	58
155	Sensitivity of Older Patients to Antipsychotic Motor Side Effects: A PET Study Examining Potential Mechanisms. American Journal of Geriatric Psychiatry, 2009, 17, 255-263.	1.2	58
156	â€œExtendedâ€•Antipsychotic Dosing in the Maintenance Treatment of Schizophrenia. Journal of Clinical Psychiatry, 2011, 72, 1042-1048.	2.2	58
157	Do Antipsychotics Improve Reasoning Biases? A Review. Psychosomatic Medicine, 2010, 72, 681-693.	2.0	57
158	The Antipsychotics Olanzapine, Risperidone, Clozapine, and Haloperidol Are D2-Selective Ex Vivo but Not In Vitro. Neuropsychopharmacology, 2010, 35, 1826-1835.	5.4	57
159	Exploring the Neural Correlates of Delusions of Reference. Biological Psychiatry, 2011, 70, 1127-1133.	1.3	57
160	The evolution of antipsychotic switch and polypharmacy in natural practice â€” A longitudinal perspective. Schizophrenia Research, 2011, 130, 40-46.	2.0	57
161	Olanzapine. Journal of Clinical Psychopharmacology, 2013, 33, 329-335.	1.4	56
162	Functional network differences in schizophrenia. NeuroReport, 1998, 9, 1697-1700.	1.2	55

#	Article	IF	Citations
163	OralD-amphetamine causes prolonged displacement of [11C]raclopride as measured by PET. Synapse, 2004, 51, 27-31.	1.2	55
164	A sensitizing regimen of amphetamine that disrupts attentional set-shifting does not disrupt working or long-term memory. Behavioural Brain Research, 2008, 189, 170-179.	2.2	55
165	The Effects of Antipsychotic Treatment on Presynaptic Dopamine Synthesis Capacity in First-Episode Psychosis: A Positron Emission Tomography Study. Biological Psychiatry, 2019, 85, 79-87.	1.3	54
166	The antipsychotic potential of l-stepholidineâ€"a naturally occurring dopamine receptor D1 agonist and D2 antagonist. Psychopharmacology, 2008, 199, 275-289.	3.1	53
167	Effects of typical and atypical antipsychotic drugs on maternal behavior in postpartum female rats. Schizophrenia Research, 2004, 70, 69-80.	2.0	52
168	The selective effect of antipsychotics on the different dimensions of the experience of psychosis in schizophrenia spectrum disorders. Schizophrenia Research, 2006, 88, 111-118.	2.0	52
169	The relationship between subjective well-being and dopamine D2 receptors in patients treated with a dopamine partial agonist and full antagonist antipsychotics. International Journal of Neuropsychopharmacology, 2009, 12, 715.	2.1	52
170	Initial depression severity and response to antidepressants v. placebo: patient-level data analysis from 34 randomised controlled trials. British Journal of Psychiatry, 2016, 209, 427-428.	2.8	52
171	Differential Effects of Within-Day Continuous Vs Transient Dopamine D2 Receptor Occupancy in the Development of Vacuous Chewing Movements (VCMs) in Rats. Neuropsychopharmacology, 2003, 28, 1433-1439.	5.4	51
172	Dopamine and Glutamate in Antipsychotic-Responsive Compared With Antipsychotic-Nonresponsive Psychosis: A Multicenter Positron Emission Tomography and Magnetic Resonance Spectroscopy Study (STRATA). Schizophrenia Bulletin, 2021, 47, 505-516.	4.3	51
173	Ketamine has equal affinity for NMDA receptors and the high-affinity state of the dopamine d2 receptor. Biological Psychiatry, 2001, 49, 954-955.	1.3	50
174	Dopaminergic activity in depressed smokers: A positron emission tomography study. Synapse, 2009, 63, 681-689.	1.2	50
175	Phosphodiesterase 10A PET Radioligand Development Program: From Pig to Human. Journal of Nuclear Medicine, 2014, 55, 595-601.	5.0	50
176	Modafinil combined with cognitive training: Pharmacological augmentation of cognitive training in schizophrenia. European Neuropsychopharmacology, 2015, 25, 1178-1189.	0.7	50
177	A voxel-by-voxel analysis of [18F]setoperone PET data shows no substantial serotonin 5-HT2A receptor changes in schizophrenia. Psychiatry Research - Neuroimaging, 2000, 99, 123-135.	1.8	49
178	Increased dopamine D2High receptors in amphetamine-sensitized rats, measured by the agonist [3H](+)PHNO. Synapse, 2007, 61, 263-267.	1.2	49
179	The relationship between antipsychotic D2 occupancy and change in frontal metabolism and working memory. Psychopharmacology, 2013, 227, 221-229.	3.1	49
180	Evaluation of N-Desmethylclozapine as a Potential Antipsychoticâ€"Preclinical Studies. Neuropsychopharmacology, 2007, 32, 1540-1549.	5.4	47

#	Article	IF	Citations
181	Dopamine D2 receptor radiotracers [11C](+)-PHNO and [3H]raclopride are indistinguishably inhibited by D2 agonists and antagonists ex vivo. Nuclear Medicine and Biology, 2008, 35, 11-17.	0.6	47
182	The Optimization of Treatment and Management of Schizophrenia in Europe (OPTiMiSE) Trial: Rationale for its Methodology and a Review of the Effectiveness of Switching Antipsychotics. Schizophrenia Bulletin, 2015, 41, 549-558.	4.3	47
183	Connectomic correlates of response to treatment in first-episode psychosis. Brain, 2017, 140, 487-496.	7.6	47
184	Clozapine and olanzapine exhibit an intrinsic anxiolytic property in two conditioned fear paradigms: Contrast with haloperidol and chlordiazepoxide. Pharmacology Biochemistry and Behavior, 2008, 90, 551-562.	2.9	46
185	Dynamic regulation of dopamine and serotonin responses to salient stimuli during chronic haloperidol treatment. International Journal of Neuropsychopharmacology, 2011, 14, 1327-1339.	2.1	46
186	Issues and perspectives in designing clinical trials for negative symptoms in schizophrenia. Schizophrenia Research, 2013, 150, 328-333.	2.0	46
187	Monthly Administration of Long-Acting Injectable Risperidone and Striatal Dopamine D2 Receptor Occupancy for the Management of Schizophrenia. Journal of Clinical Psychiatry, 2008, 69, 1281-1286.	2.2	46
188	A Positron Emission Tomography Study of 5-Hydroxytryptamine-1A Receptors in Alzheimer Disease. American Journal of Geriatric Psychiatry, 2007, 15, 888-898.	1.2	45
189	Emerging drugs for schizophrenia. Expert Opinion on Emerging Drugs, 2008, 13, 479-495.	2.4	45
190	Modulation of cortical neuronal activity by a serotonergic agent: a PET study in humans. Brain Research, 1994, 646, 292-294.	2.2	44
191	Early onset of antipsychotic response in the treatment of acutely agitated patients with psychotic disorders. Schizophrenia Research, 2008, 102, 241-248.	2.0	44
192	Effect of antipsychotics on cortical inhibition using transcranial magnetic stimulation. Psychopharmacology, 2003, 170, 255-262.	3.1	43
193	Changes in delusions in the early phase of antipsychotic treatment â€“ An experience sampling study. Psychiatry Research, 2014, 215, 568-573.	3.3	42
194	Continuous but not intermittent olanzapine infusion induces vacuous chewing movements in rats. Biological Psychiatry, 2005, 57, 406-411.	1.3	41
195	D2 Receptor Blockade by Risperidone Correlates With Attention Deficits in Late-Life Schizophrenia. Journal of Clinical Psychopharmacology, 2009, 29, 571-575.	1.4	41
196	Evaluation of the motor initiation hypothesis of APD-induced conditioned avoidance decreases. Pharmacology Biochemistry and Behavior, 2004, 78, 811-819.	2.9	40
197	Amphetamine pretreatment induces a change in both D 2 -Receptor density and apparent affinity: a [11 C]raclopride positron emission tomography study in cats. Biological Psychiatry, 2004, 55, 1188-1194.	1.3	40
198	Quetiapine Extended-Release Versus Immediate-Release Formulation. Journal of Clinical Psychiatry, 2008, 69, 81-86.	2.2	40

#	Article	IF	Citations
199	Relationship Between Daily Dose, Plasma Concentrations, Dopamine Receptor Occupancy, and Clinical Response to Quetiapine. Journal of Clinical Psychiatry, 2011, 72, 1108-1123.	2.2	39
200	Aberrant Effective Connectivity in Schizophrenia Patients during Appetitive Conditioning. Frontiers in Human Neuroscience, 2011, 4, 239.	2.0	39
201	Loss of extra-striatal phosphodiesterase 10A expression in early premanifest Huntington's disease gene carriers. Journal of the Neurological Sciences, 2016, 368, 243-248.	0.6	37
202	Task-Independent Effect of Time on rCBF. NeuroImage, 1998, 7, 314-325.	4.2	36
203	A Model of Antipsychotic Action in Conditioned Avoidance: A Computational Approach. Neuropsychopharmacology, 2004, 29, 1040-1049.	5.4	36
204	Blockade of 5-HT2a Receptors Reduces Haloperidol-Induced Attenuation of Reward. Neuropsychopharmacology, 2007, 32, 551-561.	5.4	36
205	Detecting improvements in acute psychotic symptoms using experience sampling methodology. Psychiatry Research, 2013, 210, 82-88.	3.3	36
206	Linking Animal Models of Psychosis to Computational Models of Dopamine Function. Neuropsychopharmacology, 2007, 32, 54-66.	5.4	35
207	Trajectories of response to treatment with atypical antipsychotic medication in patients with schizophrenia pooled from 6 double-blind, randomized clinical trials. Schizophrenia Research, 2011, 130, 11-19.	2.0	34
208	Activation of specific cortical regions by apomorphine: an [15O]H2O PET study in humans. Neuroscience Letters, 1994, 176, 21-24.	2.1	33
209	Neuromodulation of frontal and temporal cortex by intravenous d-fenfluramine: an [15O]H2O PET study in humans. Neuroscience Letters, 1996, 207, 25-28.	2.1	33
210	Phosphodiesterase 10A in Schizophrenia: A PET Study Using [¹¹C]IMA107. American Journal of Psychiatry, 2016, 173, 714-721.	7.2	33
211	Longitudinal in vivo maturational changes of metabolites in the prefrontal cortex of rats exposed to polyinosinicâ€“polycytidylic acid in utero. European Neuropsychopharmacology, 2015, 25, 2210-2220.	0.7	32
212	Reliability of a simple non-invasive method for the evaluation of 5-HT2 receptors using [18F]-setoperone PET imaging. Nuclear Medicine Communications, 1997, 18, 395-399.	1.1	31
213	Calibration and cross-validation of MCCB and CogState in schizophrenia. Psychopharmacology, 2015, 232, 3873-3882.	3.1	31
214	A Computational Model of the Functional Role of the Ventral-Striatal D2 Receptor in the Expression of Previously Acquired Behaviors. Neural Computation, 2005, 17, 361-395.	2.2	30
215	How antipsychotics work: The patients' perspective. Progress in Neuro-Psychopharmacology and Biological Psychiatry, 2005, 29, 859-864.	4.8	30
216	Effects of chronic typical and atypical antipsychotic drug treatment on maternal behavior in rats. Schizophrenia Research, 2005, 75, 325-336.	2.0	30

#	Article	IF	Citations
217	Attribution style as a factor in psychosis and symptom resolution. Schizophrenia Research, 2008, 104, 220-227.	2.0	30
218	Moment-to-moment associations between negative affect, aberrant salience, and paranoia. Cognitive Neuropsychiatry, 2018, 23, 299-306.	1.3	30
219	Mapping Neural Interactivity onto Regional Activity: An Analysis of Semantic Processing and Response Mode Interactions. NeuroImage, 1998, 7, 244-254.	4.2	29
220	Increasing D2 affinity results in the loss of clozapineÊ¼s atypical antipsychotic action. NeuroReport, 2002, 13, 831-835.	1.2	29
221	"Extended" Antipsychotic Dosing. Journal of Clinical Psychopharmacology, 2005, 25, 611-613.	1.4	29
222	Re-examining the role of benzodiazepines in the treatment of schizophrenia: A systematic review. Journal of Psychopharmacology, 2015, 29, 212-223.	4.0	29
223	Amoxapine as an Atypical Antipsychotic: A Comparative Study Vs Risperidone. Neuropsychopharmacology, 2005, 30, 2236-2244.	5.4	28
224	Predicting Brain Occupancy from Plasma Levels using PET: Superiority of Combining Pharmacokinetics with Pharmacodynamics while Modeling the Relationship. Journal of Cerebral Blood Flow and Metabolism, 2012, 32, 759-768.	4.3	28
225	The effects of a single dose of oxytocin on working memory in schizophrenia. Schizophrenia Research, 2015, 162, 62-63.	2.0	28
226	Drug-induced receptor occupancy: substantial differences in measurements made in vivo vs ex vivo. Psychopharmacology, 2001, 157, 168-171.	3.1	27
227	Rapid antipsychotic response with ziprasidone predicts subsequent acute manic/mixed episode remission. Journal of Psychiatric Research, 2010, 44, 8-14.	3.1	27
228	Dopamine-induced changes in neural network patterns supporting aversive conditioning. Brain Research, 2010, 1313, 143-161.	2.2	27
229	Effects of aging on 5â€HT_{2A}R binding: a HRRT PET study with and without partial volume corrections. International Journal of Geriatric Psychiatry, 2011, 26, 1300-1308.	2.7	26
230	The effect of perinatal brain injury on dopaminergic function and hippocampal volume in adult life. ELife, 2017, 6, .	6.0	26
231	Use of random-sequence riboflavin as a marker of medication compliance in chronic schizophrenics. Schizophrenia Research, 1991, 6, 49-53.	2.0	24
232	Quantitative validation of an intracerebral ?-sensitive microprobe system to determine in vivo drug-induced receptor occupancy using [11C]raclopride in rats. Synapse, 2004, 52, 89-99.	1.2	24
233	Treatment Response to Olanzapine and Haloperidol and its Association with Dopamine D₂ Receptor Occupancy in First-Episode Psychosis. Canadian Journal of Psychiatry, 2005, 50, 462-469.	1.9	24
234	In vivo characterization of the pharmacokinetics and pharmacological properties of [11C]-(+)-PHNO in rats using an intracerebral beta-sensitive system. Synapse, 2006, 60, 172-183.	1.2	24

#	Article	IF	Citations
235	The neurobiology of schizophrenia: new leads and avenues for treatment. Current Opinion in Neurobiology, 2010, 20, 810-815.	4.2	24
236	Is desire for social relationships mediated by the serotonergic system in the prefrontal cortex? An [¹⁸F]setoperone PET study. Social Neuroscience, 2010, 5, 375-383.	1.3	24
237	Partial agonists in schizophrenia â€“ why some work and others do not: insights from preclinical animal models. International Journal of Neuropsychopharmacology, 2011, 14, 1165-1178.	2.1	24
238	Ex vivo [¹¹C]â€(+)â€PHNO binding is unchanged in animal models displaying increased highâ€affinity states of the D₂receptor in vitro. Synapse, 2009, 63, 998-1009.	1.2	23
239	Treating impaired cognition in schizophrenia: The case for combining cognitive-enhancing drugs with cognitive remediation. European Neuropsychopharmacology, 2013, 23, 790-798.	0.7	23
240	The Relationship Between Risperidone Plasma Levels and Dopamine D (2) Occupancy. Journal of Clinical Psychopharmacology, 1998, 18, 82-83.	1.4	23
241	Effects of novel antipsychotics, amisulpiride and aripiprazole, on maternal behavior in rats. Psychopharmacology, 2005, 181, 600-610.	3.1	22
242	Challenging the assumption that improvement in functional outcomes is delayed relative to improvement in symptoms in the treatment of schizophrenia. Schizophrenia Research, 2010, 118, 176-182.	2.0	22
243	Tetrabenazine Augmentation in Treatment-Resistant Schizophrenia. Journal of Clinical Psychopharmacology, 2012, 32, 95-99.	1.4	22
244	Dopamine D2 Receptor Blockade by Haloperidol 3H-Raclopride Reveals Much Higher Occupancy than EEDQ. Neuropsychopharmacology, 2000, 23, 595-598.	5.4	21
245	Clozapine can induce high dopamine D 2 receptor occupancy in vivo. Psychopharmacology, 2002, 160, 107-112.	3.1	21
246	Effects of the dopamine stabilizer, OSU-6162, on brain stimulation reward and on quinpirole-induced changes in reward and locomotion. European Neuropsychopharmacology, 2009, 19, 416-430.	0.7	21
247	Electroconvulsive shock increases tyrosine hydroxylase and neuropeptide Y gene expression in the locus coeruleus. Molecular Brain Research, 1993, 18, 121-126.	2.3	18
248	Amoxapine shows atypical antipsychotic effects in patients with schizophrenia: results from a prospective open-label study. Schizophrenia Research, 2003, 59, 35-39.	2.0	18
249	Variations of restÂâ€“Âactivity rhythm and sleepÂâ€“Âwake in schizophrenic patients versus healthy subjects: An actigraphic comparative study. Biological Rhythm Research, 2008, 39, 69-78.	0.9	18
250	Establishing Testâ€“Retest Reliability of an Adapted [¹⁸F]Fallypride Imaging Protocol in Older People. Journal of Cerebral Blood Flow and Metabolism, 2013, 33, 1098-1103.	4.3	18
251	Molecular imaging as a guide for the treatment of central nervous system disorders. Dialogues in Clinical Neuroscience, 2013, 15, 315-328.	3.7	18
252	Actigraphic measurement of the effects of single-dose haloperidol and olanzapine on spontaneous motor activity in normal subjects. Journal of Psychiatry and Neuroscience, 2003, 28, 293-9.	2.4	18

#	Article	IF	Citations
253	Amoxapine as an Antipsychotic. Journal of Clinical Psychopharmacology, 2007, 27, 575-581.	1.4	17
254	Amoxapine Shows an Antipsychotic Effect but Worsens Motor Function in Patients with Parkinson's Disease and Psychosis. Clinical Neuropharmacology, 2001, 24, 242-244.	0.7	16
255	EMD 281014, a specific and potent 5HT2 antagonist in humans: a dose-finding PET study. Psychopharmacology, 2004, 175, 382-388.	3.1	16
256	Looking for a â€œbiological testâ€•to diagnose â€œschizophreniaâ€• are we chasing red herrings?. World Psychiatry, 2011, 10, 32-32.	10.4	16
257	Relationship between central and peripheral serotonin 5-HT2A receptors: a positron emission tomography study in healthy individuals. Neuroscience Letters, 1999, 261, 139-142.	2.1	15
258	Gestational treatment with methylazoxymethanol (MAM) that disrupts hippocampal-dependent memory does not alter behavioural response to cocaine. Pharmacology Biochemistry and Behavior, 2009, 93, 382-390.	2.9	13
259	How antipsychotics impact the different dimensions of Schizophrenia: A test of competing hypotheses. European Neuropsychopharmacology, 2014, 24, 1279-1288.	0.7	13
260	Contrasting loxapine to its isomer isoloxapineâ€”the critical role of in vivo D2 blockade in determining atypicality. Schizophrenia Research, 2005, 77, 189-199.	2.0	12
261	The use of healthy volunteers instead of patients to inform drug dosing studies: a [11C]raclopride PET study. Psychopharmacology, 2011, 217, 515-523.	3.1	12
262	Early improvement on antipsychotic treatment as a predictor of subsequent response in schizophrenia: analyses from ziprasidone clinical studies. Human Psychopharmacology, 2011, 26, 282-290.	1.5	12
263	Dopamine, Striatum, Antipsychotics, and Questions About Weight Gain. JAMA Psychiatry, 2016, 73, 107.	11.0	12
264	Antipsychoticlike effects of amoxapine, without catalepsy, using the prepulse inhibition of the acoustic startle reflex test in rats. Biological Psychiatry, 2000, 47, 670-676.	1.3	11
265	Effect of acute antipsychotic administration on dopamine synthesis in rodents and human subjects using 6-[18F]-L-m-tyrosine. Synapse, 2004, 52, 153-162.	1.2	11
266	Haloperidol modulates noradrenergic responses to aversive stimulation depending on treatment duration. Behavioural Brain Research, 2011, 221, 311-313.	2.2	11
267	UK Doubles Its â€œWorld-Leadingâ€•Research in Life Sciences and Medicine in Six Years: Testing the Claim?. PLoS ONE, 2015, 10, e0132990.	2.5	11
268	Increasing Versus Maintaining the Dose of Olanzapine or Risperidone in Schizophrenia Patients Who Did Not Respond to a Modest Dosage. Journal of Clinical Psychiatry, 2016, 77, 1381-1390.	2.2	11
269	The newer antipsychotics: underlying mechanisms and the new clinical realities. Current Opinion in Psychiatry, 2004, 17, 115-121.	6.3	10
270	BL-1020, a novel antipsychotic candidate with GABA-enhancing effects: D2 receptor occupancy study in humans. European Neuropsychopharmacology, 2009, 19, 841-850.	0.7	10

#	Article	IF	Citations
271	Early Onset of Antipsychotic Action in Schizophrenia. Journal of Clinical Psychopharmacology, 2010, 30, 286-289.	1.4	10
272	Predicting clinical response in people at ultra-high risk of psychosis: a systematic and quantitative review. Drug Discovery Today, 2015, 20, 924-927.	6.4	9
273	Calculating Occupancy when One does not have Baseline: A Comparison of Different Options. Journal of Cerebral Blood Flow and Metabolism, 2011, 31, 1760-1767.	4.3	8
274	Clinical trials for negative symptoms â€" Emerging directions and unresolved issues. Schizophrenia Research, 2013, 150, 327.	2.0	8
275	Effects of haloperidol and aripiprazole on the human mesolimbic motivational system: A pharmacological fMRI study. European Neuropsychopharmacology, 2015, 25, 2252-2261.	0.7	8
276	Adenosine A2A receptor in schizophrenia: an in vivo brain PET imaging study. Psychopharmacology, 2022, 239, 3439-3445.	3.1	8
277	Receptor Occupancy by Antipsychotics â€" Concepts and Findings. Handbooks of Pharmacology and Toxicology, 2000, , 163-176.	0.1	8
278	Brain Activation During Affective Visual Cues in Schizophrenia. Journal of Clinical Psychopharmacology, 2004, 24, 450-452.	1.4	7
279	Dopamine Receptors and the Treatment of Schizophrenia. Receptors, 2010, , 431-477.	0.2	7
280	New insights into schizophrenia from neuroimaging. Current Opinion in Psychiatry, 1998, 11, 33-37.	6.3	7
281	The effects of reality distortion syndrome on salient stimuli processing in patients with schizophrenia: An fMRI study. Psychiatry Research - Neuroimaging, 2010, 183, 93-98.	1.8	6
282	Going Beyond "trial-and-error" in Psychiatric Treatments: OPTiMiSE-ing the Treatment of First Episode of Schizophrenia. Schizophrenia Bulletin, 2015, 41, 546-548.	4.3	6
283	Mobile early detection and connected intervention to coproduce better care in severe mental illness. Studies in Health Technology and Informatics, 2015, 216, 123-6.	0.3	6
284	Comment on â€œketamine has equal affinity for NMDA receptors and the high-affinity state of the dopamine D2 receptorâ€• Reply. Biological Psychiatry, 2001, 50, 555-556.	1.3	5
285	Relation between cortical dopamine D2 receptor occupancy and suppression of conditioned avoidance response in non-human primate. Psychiatry and Clinical Neurosciences, 2004, 58, 330-332.	1.8	5
286	What Kraepelin might say about schizophrenia: Just the facts. Schizophrenia Research, 2011, 128, 1-2.	2.0	5
287	NEWMEDS special issue commentary. Psychopharmacology, 2015, 232, 3849-3851.	3.1	5
288	Biomarkers of treatment outcome in schizophrenia: Defining a benchmark for clinical significance. European Neuropsychopharmacology, 2015, 25, 1578-1585.	0.7	5

#	Article	IF	Citations
289	Small Sample Sizes and a False Economy for Psychiatric Clinical Trials. JAMA Psychiatry, 2019, 76, 676.	11.0	5
290	Changes in delusional dimensions and emotions over eight weeks of antipsychotic treatment in acute patients. Psychiatry Research, 2015, 228, 393-398.	3.3	4
291	Quantification of l-stepholidine in rat brain and plasma by high performance liquid chromatography combined with fluorescence detection. Journal of Chromatography B: Analytical Technologies in the Biomedical and Life Sciences, 2007, 850, 544-547.	2.3	3
292	Disaster mental health in Asia and the Asian Journal of Psychiatry. Asian Journal of Psychiatry, 2008, 1, 5-6.	2.0	2
293	Ventajas y desventajas del tratamiento de combinaciÃ³n con antipsicÃ³ticos. ReuniÃ³n ECNP Consensus, marzo de 2008, Niza. Psiquiatria Biologica, 2011, 18, 55-67.	0.1	2
294	Combining efficacy and completion rates with no data imputation: A composite approach with greater sensitivity for the statistical evaluation of active comparisons in antipsychotic trials. European Neuropsychopharmacology, 2014, 24, 357-368.	0.7	2
295	Antipsychotics Circa 2020: What are we thinking?. Neuropharmacology, 2020, 175, 108181.	4.1	2
296	New and old antipsychotics: what â€˜effectivenessâ€™ trials tell us. Psychiatry (Abingdon, England), 2008, 7, 443-446.	0.2	1
297	The Optimization of Treatment and Management of Schizophrenia in Europe (OPTiMiSE) Trial: Rationale for Its Methodology and a Review of the Effectiveness of Switching Antipsychotics. Focus (American) Tj ETQq1 1 0.784314 rgBT /Ove		lo
298	How change comes: translating biological research into care. The Psychiatrist, 2011, 35, 321-324.	0.3	1
299	The Role of Neuroimaging in Development of and Treatment With Antipsychotics. Journal of Pharmacy Practice, 2001, 14, 332-340.	1.0	0
300	Review: amisulpride is effective and safe for schizophrenia. Evidence-Based Mental Health, 2002, 5, 85-85.	4.5	0
301	Functional Neuroimaging in Psychiatry. , 0, , 167-193.		0
302	Imaging of brain structure and function: relevance to psychiatric disorders. , 0, , 68-79.		0
303	Reply to: Lithium and the Expanding Brain. Biological Psychiatry, 2012, 72, e19.	1.3	0
304	Polypharmacy: the good, the bad and the ugly. International Journal of Neuropsychopharmacology, 2014, 17, 981.	2.1	0
305	From Dopamine to Psychosis: A Computational Approach. Lecture Notes in Computer Science, 2003, , 1115-1121.	1.3	0
306	PET imaging of DA neurotransmission using agonist versus antagonist radiotracers. Journal of Cerebral Blood Flow and Metabolism, 2005, 25, S715-S715.	4.3	0

#	Article	IF	Citations
307	The D2-agonist radiotracer [11C]-(+)-PHNO shows a marked increase in sensitivity to amphetamine challenges when compared to [11C]raclopride in the cat brain. Journal of Cerebral Blood Flow and Metabolism, 2005, 25, S611-S611.	4.3	0
308	Evaluation of [11C]-(+)-PHNO as an agonist radiotracer for imaging high-affinity dopamine D2 receptors. Journal of Cerebral Blood Flow and Metabolism, 2005, 25, S594-S594.	4.3	0
309	10.3 How Antipsychotics Work: Linking Receptors to Response. , 2009, , 540-557.		0
310	Aminergic Hypothesis for Schizophrenia. , 2013, , 1-6.		0
311	The Enduring Centrality of Dopamine in the Pathophysiology of Schizophrenia. , 2014, , 151-152.		0